HomeNewsBusinessEconomyDirect monetisation still on the table as govt prepares stimulus package

Direct monetisation still on the table as govt prepares stimulus package

The govt is helped by increased purchase of G-secs by the RBI through OMOs. For April 1-Sept 13 2020, the RBI purchased Rs 1.76 lakh crore worth of G-secs on the secondary market. This is more than three times the Rs 52,550 crore of G-secs that it bought in the same period last year.

September 22, 2020 / 15:36 IST
Story continues below Advertisement
File image
File image

The Finance Ministry may not take up the option of direct monetisation of the Centre's deficit by the Reserve Bank of India for now. However, that option has not been completely ruled out and may still be considered before the January-March FY21 quarter, two government officials told Moneycontrol.

On September 30, the RBI is expected to announce the borrowing calendar for October-March. Out of the expanded borrowing target of Rs 12 lakh crore, the Centre has already borrowed around Rs 7.4 lakh crore through issuance of G-secs. For now, the second half borrowing quantum could be on expected lines, a little over 4.5 lakh crore, said one of the officials.

Story continues below Advertisement

"For now, the borrowing requirements are not higher than Rs 12 trillion. However, a call on additional borrowing may be taken closer to the last quarter," the person said.

The factors which policymakers in the central government will consider could include the need for another round of fiscal stimulus, revenue position by the end of the October-December quarter, and the state of the economy, as the July-September gross domestic product data will also be released by then.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show